HPV, Cytology, and Cotest Cervical Cancer Screening and the Risk of Precancer
In this cohort study of cervical cancer screen testing approaches and risk of cervical precancer, after a negative HPV test (regardless of cytology results) risk of precancer remained acceptably low throughout long-term follow-up. This suggests that cotesting yielded limited benefits, while increasing costs, relative to primary HPV testing.
Authors
- Lily Proctor (ORCID: https://orcid.org/0000-0003-0264-4793)
- Anna Gottschlich (ORCID: https://orcid.org/0000-0002-3095-2323)
- Joy Melnikow (ORCID: https://orcid.org/0000-0002-9963-6089)
- Ruth Elwood Martin (ORCID: https://orcid.org/0000-0001-7592-3692)
- Smritee Dabee (ORCID: https://orcid.org/0000-0002-8373-9593)
- Gavin Stuart (ORCID: https://orcid.org/0000-0002-8815-4607)
- Darrel Cook (ORCID: https://orcid.org/0000-0002-1958-120X)
- Stuart Peacock (ORCID: https://orcid.org/0000-0002-8243-8721)
- Quan Hong
- Gina S. Ogilvie
- Mel Krajden
- Lovedeep Gondara
- Laurie W. Smith
- Eduardo L. Franco
Institutions
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Simon Fraser University (CA)
- Wayne State University (US)
- BC Centre for Disease Control (CA)
- The Barbara Ann Karmanos Cancer Institute (US)
- Women's Health Research Institute (CA)
- McGill University (CA)
- University of California, Davis (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.1304
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- McGill University
- Michael Smith Health Research BC
- Partenariat Canadien Contre Le Cancer
- National Institutes of Health
- National Cancer Institute